About Genflow Biosciences
Genflow Biosciences is a publicly listed company based in Charleroi (Belgium) founded in 2020 by Eric Leire. A biotechnology company focused on anti-aging therapeutics development. It operates on a HealthTech model. Its chief executive, as recorded, is Eric Leire. Genflow Biosciences offers products and services including GF-1002. Its focus areas include Biotechnology and Gene Therapy. Its legal entity is Genflow Biosciences plc. Its competitors include MaSTherCell and Exothera; 1 of its 2 listed competitors has raised funding.
Company details
Genflow Biosciences is engaged in the research and development of novel therapeutic solutions aimed at slowing or halting the aging process in humans and dogs. Based in the UK, the company operates with RD facilities in Belgium and focuses on innovative gene therapies, such as the GF-1002 compound, which utilizes a centenarian variant of the SIRT6 gene. Their work targets the reduction of healthcare costs and addresses social challenges associated with aging populations through direct intervention in biological aging mechanisms.
- Headquarters Charleroi, Belgium
- Founders Eric Leire
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website genflowbio.com
- Social LinkedIn X Instagram
- Legal Name Genflow Biosciences Plc
- Net Profit-$1.91 M (USD)10.69as on Dec 31, 2025
- EBITDA-$2.69 M (USD)-5.01as on Dec 31, 2025
- Latest Funding Round$1.31M (USD), Grant
Oct 2024
- InvestorsWallonia
& 1 more
Products & Services of Genflow Biosciences
Genflow Biosciences offers a comprehensive portfolio of products and services, including GF-1002.
A compound targeting aging through SIRT6 gene delivery.
Funding Insights of Genflow Biosciences
- Total Rounds 3
- Last Round Grant — $1.31M
- First Round $3.7M
(Mar 2022)
- Investors Count 2
All 3 funding rounds of Genflow Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2024 | $1.31M | Grant | – | – | |
| Apr 2024 | $901,086 | Post-IPO | – | – | |
| Mar 2022 | $3.7M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Genflow Biosciences
Genflow Biosciences has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Wallonia and Capital Plus Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Access to government programs and development services is facilitated. | 1970 | wallonie.be | Belgium | |
| capplus.co.uk |
Investor details for Genflow Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genflow Biosciences
11 people are tracked at Genflow Biosciences (2 in leadership, 9 in board & advisors).
| Name | Role | Group |
|---|---|---|
Eric Leire | Founder & CEO | Leadership |
Cedric Szpirer | Head of CMC | Leadership |
Vera Gorbunova | Scientific Advisor | Board & advisors |
Eric Verdin | Scientific Advisor | Board & advisors |
Manlio Vinciguerra | Scientific Advisor | Board & advisors |
Matthew Hirschey | Scientific Advisor | Board & advisors |
Guy Charles Fanneau de la Horie | Director | Board & advisors |
Yassine Bendiabdallah | Chairman | Board & advisors |
Tamara Joseph | Non-Executive Director | Board & advisors |
Peter King-Lewis | Non-Executive Director | Board & advisors |
J. Jeneva L. Patterson she/her/hers | Non Executive Director | Board & advisors |
Complete people profiles for Genflow Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Genflow Biosciences
Genflow Biosciences is a publicly listed company on the LSE with ticker symbol GENF in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Jan 2022
- Listed onLSE: GENF
- Listed entityGenflow Biosciences Plc
- Exchange sectorHealth technology
- ISINGB00BP2C3V08
- Share price1.77 GBX (-1.78% on the day) · 2026-10-14
- Market capitalisation10,701,625.00 GBX
- EPS (diluted, trailing year)-0.00 GBX
- Volume (last session)172,361
Financials of Genflow Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -1.4M GBP | -2.0M GBP | |
| 2024 | -1.6M GBP | -1.9M GBP | |
| 2023 | -1.9M GBP | -2.0M GBP | |
| 2022 | -1.3M GBP | -1.8M GBP | |
| 2021 | -988,200 GBP | -988,100 GBP |
Detailed financial statements for Genflow Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Genflow Biosciences
4 dated milestones of Genflow Biosciences across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Genflow Biosciences is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $3.7M.
- Funding Latest funding round, Grant, of $1.3M.
Competitors of Genflow Biosciences
Genflow Biosciences has 2 listed competitors in our database, 1 of them funded. They include MaSTherCell and Exothera.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| masthercell.com | 2011 | Charleroi, Belgium | $17.37M | 329 | Services for cell therapy development and manufacturing are provided. | |
| exothera.world | 2020 | Brussels, Belgium | 131 | Clinical trial services to biopharma sector are provided by CDMO. |
Detailed competitors of Genflow Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Genflow Biosciences
The website of Genflow Biosciences (genflowbio.com) receives about 8.4K visits a month.
- Monthly visits8.4K
▲ 4.6% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genflow Biosciences
Complete news archive for Genflow Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genflow Biosciences
Genflow Biosciences was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Genflow Biosciences is headquartered in Charleroi, Belgium. It is registered at Charleroi, Walloon Region, Belgium.
Eric Leire is the CEO of Genflow Biosciences, as recorded in our data. They have also founded this company.
Genflow Biosciences is engaged in the research and development of novel therapeutic solutions aimed at slowing or halting the aging process in humans and dogs. Based in the UK, the company operates with RD facilities in Belgium and focuses on innovative gene therapies, such as the GF-1002 compound, which utilizes a centenarian variant of the SIRT6 gene. Their work targets the reduction of healthcare costs and addresses social challenges associated with aging populations through direct intervention in biological aging mechanisms.
Genflow Biosciences's top competitors include MaSTherCell and Exothera.
Genflow Biosciences offers GF-1002.
Yes, Genflow Biosciences is publicly traded on LSE under the ticker symbol GENF.
Genflow Biosciences has 2 investors. Key investors include Wallonia, and Capital Plus Partners.
Genflow Biosciences operates through Genflow Biosciences Plc.